Brendan O'Grady reports a stock award at Nasus Pharma
By AlphaYouPublished Form 4
O'Grady Brendan P.
Reporting filer
Brendan O'Grady reports a stock award, not an open-market purchase or sale, in Nasus Pharma Ltd. Form 4 filed Nov 14, 2026 lists 1 entry.
- Disclosed
- Nov 14, 2026
Reported details
1 entry| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Share options (right to buy) (derivative) | O'Grady Brendan P. | 2026-10-08 | A | Grant or award | 210000 | Not stated (see footnotes) | 210,000 | 37 days | Filed terms
|
Share options (right to buy) (derivative)
- Owner
- O'Grady Brendan P.
- Date
- 2026-10-08
- Code
- A
- Action
- Grant or award
- Quantity
- 210000
- Price
- Not stated (see footnotes)
- Following holdings
- 210,000
- Reporting delay
- 37 days
- Filed terms and references
Filed terms
- security Title: Share options (right to buy)
- id: F2
- transaction Date: 2026-10-08
- deemed Execution Date:
- transaction Form Type: 4
- transaction Code: A
- equity Swap Involved: 0
- transaction Timeliness:
- transaction Shares: 210000
- id: F2
- transaction Acquired Disposed Code: A
- exercise Date: 2027-07-27
- id: F1
- expiration Date: 2036-07-27
- underlying Security Title: Ordinary Shares
- underlying Security Shares: 210000
- shares Owned Following Transaction: 210000
- direct Or Indirect Ownership: D
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- O'Grady Brendan P.: Chief Executive Officer, Director.
- F1: Options to purchase 210,000 ordinary shares of the Issuer, no par value ("Ordinary Shares"), were granted on July 27, 2026, with one-third of such options, representing 70,000 options, vesting on July 27, 2027, and the remaining two-thirds vesting in eight equal quarterly installments of 17,500 options, beginning on October 27, 2027. The foregoing options are part of the reporting person's compensation package as the Chief Executive Officer of the Issuer, which was approved by the Issuer's shareholders on October 8, 2026.
- F2: Of the 210,000 options reported herein, the first one-third, representing 70,000 options, will be exercisable at $3.50 per Ordinary Share, the second one-third, representing 70,000 options, will be exercisable at $4.25 per Ordinary Share, and the final one-third, representing 70,000 options, will be exercisable at $5.00 per Ordinary Share; provided that the exercise price of an option may not be less than the Fair Market Value of an Ordinary Share, as defined pursuant to the Issuer's 2019 Incentive Option Plan, including, without limitation, the Sub-Plan for U.S. Persons, on the grant date.
Original sources
Prepared automatically from public filing data. Report a correction.